英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
Viertel查看　Viertel　在百度字典中的解释百度英翻中〔查看〕
Viertel查看　Viertel　在Google字典中的解释Google英翻中〔查看〕
Viertel查看　Viertel　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • U. S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET . . .
    U S FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
  • Nexletol shows CLEAR benefit in cardiovascular outcome trial
    New data for Esperion’s cholesterol lowering daily pill Nexletol, used when statins are not working in people at risk of a heart attack, could inject some momentum into the drug’s slow rollout
  • Bempedoic Acid and Cardiovascular Outcomes in Statin . . .
    The risk of death from cardiovascular causes, nonfatal stroke, or nonfatal myocardial infarction (the first key secondary end point) was 15% lower with bempedoic acid than with placebo, and the
  • U. S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET . . .
    ANN ARBOR, Mich , March 22, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the United States Food and Drug Administration (FDA) has approved broad new label expansions for NEXLETOL ® (bempedoic acid) Tablets and NEXLIZET ® (bempedoic acid and ezetimibe) Tablets based on positive CLEAR Outcomes data that include indications for cardiovascular risk reduction and expanded
  • NEXLIZET® NEXLETOL® Other Outcomes Trial Information
    The most common adverse reactions in the cardiovascular outcomes trial for bempedoic acid, a component of NEXLIZET and NEXLETOL, at an incidence of ≥2% and 0 5% greater than placebo were hyperuricemia, renal impairment, anemia, elevated liver enzymes, muscle spasms, gout, and cholelithiasis
  • Therapeutic Value of SGLT2 Inhibitors in the Management of . . .
    SGLT2 inhibitors have transformed the treatment of cardiovascular disease, providing substantial therapeutic promise for a wide range of patients They are anticipated to become more and more important in the prevention and management of cardiovascular disease
  • What Is NEXLETOL®? - Learn More About This Nonstatin Option
    The most common side effects of NEXLETOL in people with heart problems include: Kidney problems, anemia, increased liver enzymes, muscle spasms, and gallstones NEXLETOL can cause serious side effects, including: Increased levels of uric acid in the blood, which can lead to gout, a painful joint condition
  • FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to . . .
    Esperion announced that the FDA approved broad new label expansions for NEXLETOL® (bempedoic acid) Tablets and NEXLIZET® (bempedoic acid and ezetimibe) Tablets based on positive CLEAR Outcomes data that include indications for cardiovascular risk reduction and expanded LDL-C lowering in both primary and secondary prevention patients
  • SGLT2 Inhibitors Shown to Improve Outcomes in Amyloid Heart . . .
    SGLT2 inhibitors were associated with significantly lower 12-month all-cause mortality and hospitalization in patients with heart failure due to ATTR, a study shows
  • U. S. FDA Approves Broad New Labels for Esperion’s NEXLETOL . . .
    U S FDA approves broad new labels for NEXLETOL® (bempedoic acid) Tablets and NEXLIZET® (bempedoic acid and ezetimibe) Tablets to prevent heart attacks and cardiovascular procedures in both primary and secondary prevention patients, regardless of statin use





中文字典-英文字典  2005-2009